微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2014, Vol. 6 ›› Issue (1): 25-29.doi: 10.3969/j.issn.1674-5671.2014.01.06

• 临床研究 • 上一篇    下一篇

ERCC1、BAG-1及BRCA1基因在非小细胞肺癌中的表达及其与预后的关系

  

  1. 广西医科大学第一附属医院心胸外科
  • 出版日期:2014-03-25 发布日期:2014-04-10
  • 通讯作者: 冼 磊 E-mail:xianlei59@163.com
  • 基金资助:

    广西科学研究与技术开发计划项目（桂科攻10124001A-44）；广西留学回国人员科学基金资助项目（桂科回0832011）； 广西卫生厅科研基金资助课题（Z2011329）

Expression and prognostic significance of ERCC1 BAG-1 and BRCA1 mRNA in non-small cell lung cancer

  • Online:2014-03-25 Published:2014-04-10

PDF (PC)

652

赞

被引次数

2

摘要： 目的 探讨ERCC1、BAG-1和BRCA1基因mRNA在接受以铂类为基础辅助化疗的非小细胞肺癌（non-small cell lung cancer，NSCLC）患者中的表达情况及其与预后的关系。方法 85例NSCLC患者中74例给予以铂类为基础的术后辅助化疗，采集全组患者的肿瘤组织和其中34例患者的癌旁组织，应用半定量RT-PCR法，检测其ERCC1、BAG-1和BRCA1基因mRNA的表达情况，回顾性分析患者的临床病理资料，探讨3个基因的表达与患者总生存期（OS）之间的关系。结果 ①ERCC1、BAG-1阴性表达的患者OS显著长于阳性表达的患者（P均=0.001）。ERCC1、BAG-1阴性表达的患者接受铂类化疗的疗效显著优于阳性表达的患者（P=0.002、P=0.001）。②BRCA1阴性表达的患者OS长于阳性表达的患者，但差异无统计学意义（P=0.057）。③多因素分析显示ERCC1、BAG-1可作为NSCLC患者接受铂类化疗的预后指标（P=0.027、P=0.022）。结论 检测ERCC1和BAG-1的表达可作为指导NSCLC患者术后接受铂类化疗及预后评估的指标。

关键词: 肺肿瘤, 非小细胞肺癌, ERCC1, BAG-1, BRCA1, 化疗, 预后

Abstract: Objective To investigate the expression and prognostic usefulness of ERCC1，BAG-1 and BRCA1 in patients with non-small cell lung cancer（NSCLC） treated with platinum-based adjuvant chemotherapy. Methods RT-PCR was used to investigate the mRNA expression of ERCC1，BAG-1 and BRCA1 in 85 samples of NSCLC tissues and 34 tumor-adjacent tissues.Relationships of the expression of these three genes with overall survival（OS） were analyzed. Results ①OS was significantly longer in patients negative for ERCC1 or BAG-1 mRNA expression than in those positive for expression of either gene（P=0.001）.Platinum-based chemotherapy was more effective for patients negative for ERCC1 or BAG-1 than for the corresponding positive patients（P=0.001 and P=0.002）， respectively.②OS may be longer in patients negative for BRCA1 mRNA expression than in BRCA1-positive patients （P=0.052）. ③Multivariate analysis suggests that ERCC1 and BAG-1 may be prognostic indicators for patients receiving platinum-based adjuvant chemotherapy（P=0.027 and P=0.022）. Conclusion Expression of ERCC1 and BAG-1 mRNA may be useful in the prognosis of NSCLC treated with platinum.

Key words: Lung neoplasm, Non-small cell lung cancer, ERCC1, BAG-1, BRCA1, Chemotherapy, Prognosis